Table of Contents
Hepatitis Research and Treatment
Volume 2010 (2010), Article ID 182067, 8 pages
http://dx.doi.org/10.1155/2010/182067
Review Article

Rituximab Administration and Reactivation of HBV

1Department of Hematology, Hakodate Municipal Hospital, Hakodate 041-8680, Japan
2Department of Internal Medicine, Hakodate Municipal Hospital, 1-10-1 Minato-Cho, Hakodate 041-8680, Japan
3Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate 041-8680, Japan
4Department of Hematology and Oncology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan
5Department of Gastroentelology, Hokkaido University Graduate School of Medicine, Sapporo 060-8638, Japan

Received 2 June 2010; Revised 3 September 2010; Accepted 29 September 2010

Academic Editor: Yoichi Hiasa

Copyright © 2010 Yutaka Tsutsumi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. McLaughlin, A. J. Grillo-López, and A. J. Grillo-López, “Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2825–2833, 1998. View at Google Scholar · View at Scopus
  2. K. Tobinai, Y. Kobayashi, and Y. Kobayashi, “Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma,” Annals of Oncology, vol. 9, no. 5, pp. 527–534, 1998. View at Publisher · View at Google Scholar
  3. T. Igarashi, “Re-treatment of relapsed indolent B-cell lymphoma with rituximab,” International Journal of Hematology, vol. 73, no. 2, pp. 213–221, 2001. View at Google Scholar
  4. A. Bermudez, F. Marco, E. Conde, E. Mazo, M. Recio, and A. Zubizarreta, “Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma,” Haematologica, vol. 85, no. 8, pp. 894–895, 2000. View at Google Scholar · View at Scopus
  5. V. R. Sharma, D. R. Fleming, and S. P. Slone, “Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab,” Blood, vol. 96, no. 3, pp. 1184–1186, 2000. View at Google Scholar · View at Scopus
  6. F. Suzan, M. Ammor, and V. Ribrag, “Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder,” New England Journal of Medicine, vol. 345, no. 13, article 1000, 2001. View at Publisher · View at Google Scholar · View at PubMed
  7. S. L. Goldberg, A. L. Pecora, and A. L. Pecora, “Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab,” Blood, vol. 99, no. 4, pp. 1486–1488, 2002. View at Publisher · View at Google Scholar
  8. R. M. Galbraith, A. L. Eddleston, R. Williams, A. J. Zuckerman, and K. D. Bagshawe, “Fulminating hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy,” The Lancet, vol. 2, pp. 538–530, 1975. View at Google Scholar
  9. J. H. Hoofnagle, G. M. Dusheiko, D. F. Schafer et al., “Reactivation of chronic hepatitis B virus infection by cancer chemotherapy,” Annals of Internal Medicine, vol. 96, no. 4, pp. 447–449, 1982. View at Google Scholar
  10. S. N. Thung, M. A. Gerber, F. Klion, and H. Gilbert, “Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier,” Archives of Internal Medicine, vol. 145, no. 7, pp. 1313–1314, 1985. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Y. N. Lau, C. L. Lai, and C. L. Lai, “Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients,” Quarterly Journal of Medicine, vol. 73, no. 270, pp. 911–917, 1989. View at Google Scholar · View at Scopus
  12. G. L. A. Bird, H. Smith, B. Portmann, G. J. M. Alexander, and R. Williams, “Acute liver decompensation on withdrawal of cytotoxic chemotherapy and immunosuppressive therapy in hepatitis B carriers,” Quarterly Journal of Medicine, vol. 73, no. 270, pp. 895–902, 1989. View at Google Scholar · View at Scopus
  13. R. H. S. Liang, A. S. F. Lok, C. L. Lai, T. K. Chan, D. Todd, and E. K. W. Chiu, “Hepatitis B infection in patients with lymphomas,” Hematological Oncology, vol. 8, no. 5, pp. 261–270, 1990. View at Publisher · View at Google Scholar · View at Scopus
  14. A. S. F. Lok, C.-L. Lai, and P.-C. Wu, “Hepatitis B virus infection in Chinese families in Hong Kong,” American Journal of Epidemiology, vol. 126, no. 3, pp. 492–499, 1987. View at Google Scholar · View at Scopus
  15. A. S. F. Lok, R. H. S. Liang, E. K. W. Chiu, K. L. Wong, T. K. Chan, and D. Todd, “Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study,” Gastroenterology, vol. 100, no. 1, pp. 182–188, 1991. View at Google Scholar · View at Scopus
  16. P. C. Pinto, E. Hu, M. Bernstein-Singer, L. Pinter-Brown, and S. Govindarajan, “Acute hepatic injury after the withdrawal of immunosuppressive chemotherapy in patients with hepatitis B,” Cancer, vol. 65, no. 4, pp. 878–884, 1990. View at Google Scholar · View at Scopus
  17. L. T. Soh, P. T. Ang, I. Sng, E. J. Chua, and Y. W. Ong, “Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapy,” European Journal of Cancer A, vol. 28, no. 8-9, pp. 1338–1339, 1992. View at Google Scholar · View at Scopus
  18. Y. Nakamura, T. Motokura, A. Fujita, T. Yamashita, and E. Ogata, “Severe hepatitis related to chemotherapy in hepatitis B virus carriers with hematologic malignancies: survey in Japan, 1987–1991,” Cancer, vol. 78, no. 10, pp. 2210–2215, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Kumagai, T. Takagi, and T. Takagi, “Hepatitis B virus carriers in the treatment of malignant lymphoma: an epidemiological study in Japan,” Annals of Oncology, vol. 8, no. 1, pp. S107–S109, 1997. View at Google Scholar · View at Scopus
  20. W. Yeo, P. K. S. Chan, and P. K. S. Chan, “Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors,” Journal of Medical Virology, vol. 62, no. 3, pp. 299–307, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. Tsutsumi, H. Kanamori, A. Mori, J. Tanaka, M. Asaka, M. Imamura, and N. Masauzi, “Reactivation of hepatitis B virus with rituximab,” Expert Opinion on Drug Safety, vol. 4, no. 3, pp. 599–608, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. Y. Tsutsumi, A. Shigematsu, and A. Shigematsu, “Analysis of reactivation of hepatitis B virus in the treatment of B cell non-Hodgkin's lymphoma in Hokkaido,” Annals of Hematology, vol. 88, no. 4, pp. 375–377, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. S. Czuczman, A. J. Grillo-López, and A. J. Grillo-López, “Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy,” Journal of Clinical Oncology, vol. 17, no. 1, pp. 268–276, 1999. View at Google Scholar
  24. J. A. Hernandez, R. Diloy, D. Salat, N. del Rio, X. Martinez, and J. M. Castellvi, “Fluminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotheraoy and rituximab,” Haematologica, vol. 88, article ECR22, 2003. View at Google Scholar
  25. C. Skrabs, C. Müller, H. Agis, C. Manhalter, and U. Jäger, “Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge,” Leukemia, vol. 16, no. 9, pp. 1884–1886, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. T. H. Westhoff, F. Jochimsen, and F. Jochimsen, “Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy,” Blood, vol. 102, no. 5, article 1930, 2003. View at Publisher · View at Google Scholar · View at PubMed
  27. H. J. Ng and L. C. Lim, “Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report,” Annals of Hematology, vol. 80, no. 9, pp. 549–552, 2001. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Jäeger, P. Neumeister, R. Brezinschek, G. Höfler, F. Quehenberger, W. Linkesch, and H. Sill, “Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study,” European Journal of Haematology, vol. 69, no. 1, pp. 21–26, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. I. Dervite, D. Hober, and P. Morel, “Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab,” New England Journal of Medicine, vol. 344, no. 1, pp. 68–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Rossini, S. Capalbo, M. Fumagalli et al., “Standard dose: rituximab in refractory chronic lymphocytic leukemia,” Hematology Journal, vol. 3, supplement 1, article 0827, 2002. View at Google Scholar
  31. E. Domingo-Domenech, E. González-Borco, C. Estany, A. Sureda, J. Besalduch, and A. F. de Sevilla, “Combined treatment with anti CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas,” Haematologica, vol. 87, no. 11, pp. 1229–1230, 2002. View at Google Scholar · View at Scopus
  32. Y. Tsutsumi, T. Kawamura, and T. Kawamura, “Hepatitis B virus reactivation in a case of Non-Hodgkin's lymphoma treated with chemotherapy and rituximab: necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy,” Leukemia and Lymphoma, vol. 45, no. 3, pp. 627–629, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Tsutsumi, J. Tanaka, and J. Tanaka, “Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma,” Annals of Hematology, vol. 83, no. 1, pp. 58–60, 2004. View at Publisher · View at Google Scholar · View at PubMed
  34. J. C. Wasmuth, H. P. Fischer, T. Sauerbruch, and F. L. Dumoulin, “Fatal acute liver failure due to reactivation of hepatitis B following treatment with fludarabine/cyclophosphamide/rituximab for low grade non-hodgkin's lymphoma,” European Journal of Medical Research, vol. 13, no. 10, pp. 483–486, 2008. View at Google Scholar · View at Scopus
  35. T. Sera, Y. Hiasa, and Y. Hiasa, “Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by Rituximab,” Internal Medicine, vol. 45, no. 11, pp. 721–724, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Umemura and K. Kiyosawa, “Fatal HBV reactivation in a subject with anti-HBs and anti-HBc,” Internal Medicine, vol. 45, no. 12, pp. 747–748, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. S. H. Yang and S. H. Kuo, “Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma,” Annals of Hematology, vol. 87, no. 4, pp. 325–327, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. L. G. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari, “Viral clearance without destruction of infected cells during acute HBV infection,” Science, vol. 284, no. 5415, pp. 825–829, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. G. J. M. Webster, S. Reignat, and S. Reignat, “Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms,” Hepatology, vol. 32, no. 5, pp. 1117–1124, 2000. View at Google Scholar · View at Scopus
  40. E. Foy, K. Li, C. Wang, R. Sumpter, M. Ikeda, S. M. Lemon, and M. Gale, “Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease,” Science, vol. 300, no. 5622, pp. 1145–1148, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. D. R. Taylor, S. T. Shi, P. R. Romano, G. N. Barber, and M. M. C. Lai, “Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein,” Science, vol. 285, no. 5424, pp. 107–110, 1999. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Gale, C. M. Blakely, and C. M. Blakely, “Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation,” Molecular and Cellular Biology, vol. 18, no. 9, pp. 5208–5218, 1998. View at Google Scholar · View at Scopus
  43. C. K. Hui, W. W. W. Cheung, and W. W. W. Cheung, “Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy,” Gastroenterology, vol. 131, no. 1, pp. 59–68, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. T. Umemura, E. Tanaka, and E. Tanaka, “Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan,” Clinical Infectious Diseases, vol. 47, no. 5, pp. e52–e56, 2008. View at Publisher · View at Google Scholar · View at PubMed
  45. S. Vento, F. Cainelli, and M. S. Longhi, “Reactivation of replication of hepatitis B and C viruses after immunosuppressive therapy: an unresolved issue,” Lancet Oncology, vol. 3, no. 6, pp. 333–340, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. A. L. Cheng, “Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin's lymphoma,” Blood, vol. 87, no. 3, article 1202, 1996. View at Google Scholar
  47. W. Yeo, T. C. Chan, and T. C. Chan, “Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab,” Journal of Clinical Oncology, vol. 27, no. 4, pp. 605–611, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. W. Yeo, B. Zee, and B. Zee, “Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy,” British Journal of Cancer, vol. 90, no. 7, pp. 1306–1311, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. R. Loomba, A. Rowley, R. Wesley, T. J. Liang, J. H. Hoofnagle, F. Pucino, and G. Csako, “Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy,” Annals of Internal Medicine, vol. 148, no. 7, pp. 519–528, 2008. View at Google Scholar · View at Scopus
  50. B. Coiffier, “Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: role of lamivudine prophylaxis,” Cancer Investigation, vol. 24, no. 5, pp. 548–552, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. G. K. K. Lau, H. H. Y. Yiu, and H. H. Y. Yiu, “Early is superior to deferred preemptive Lamivudine therapy for hepatitis B patients undergoing chemotherapy,” Gastroenterology, vol. 125, no. 6, pp. 1742–1749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. O. H. Al-Taie, H. Mörk, A. M. Gassel, M. Wilhelm, B. Weissbrich, and M. Scheurlen, “Prevention of hepatitis B flare-up during chemotherapy using lamivudine: case report and review of the literature,” Annals of Hematology, vol. 78, no. 5, pp. 247–249, 1999. View at Publisher · View at Google Scholar · View at Scopus
  53. F. Silvestri, A. Ermacora, and A. Ermacora, “Lamivudine allows completion of chemotherapy in lymphoma patients with hepatitis B reactivation,” British Journal of Haematology, vol. 108, no. 2, pp. 394–396, 2000. View at Publisher · View at Google Scholar · View at Scopus
  54. O. Shibolet, Y. Ilan, S. Gillis, A. Hubert, D. Shouval, and R. Safadi, “Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers,” Blood, vol. 100, no. 2, pp. 391–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Esteve, C. Saro, F. González-Huix, F. Suarez, M. Forné, and J. M. Viver, “Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis,” Gut, vol. 53, no. 9, pp. 1363–1365, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. A. M. Pelizzari, M. Motta, E. Cariani, P. Turconi, E. Borlenghi, and G. Rossi, “Frequency of hepatitis B virus mutant in asymptomatic hepatitis B virus carriers receiving prophylactic lamivudine during chemotherapy for hematologic malignancies,” Hematology Journal, vol. 5, no. 4, pp. 325–328, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. T. Cil, A. Altintas, S. Pasa, K. Bayan, T. Ozekinci, and A. Isikdogan, “Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy,” Leukemia and Lymphoma, vol. 49, no. 5, pp. 939–947, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. N. D. Simpson, P. W. Simpson, A. M. Ahmed, M. H. Nguyen, G. Garcia, E. B. Keeffe, and A. Ahmed, “Prophylaxis against chemotherapy-induced reactivation of hepatitis B virus infection with lamivudine,” Journal of Clinical Gastroenterology, vol. 37, no. 1, pp. 68–71, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. M. S. Dai, P. F. Wu, R. Y. Shyu, J. J. Lu, and T. Y. Chao, “Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration,” Liver International, vol. 24, no. 6, pp. 540–546, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. R. Idilman, “Lamivudine prophylaxis in HBV carriers with haemato-oncological malignancies who receive chemotherapy,” Journal of Antimicrobial Chemotherapy, vol. 55, no. 6, pp. 828–831, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. J. W. Jang, J. Y. Choi, and J. Y. Choi, “A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization,” Hepatology, vol. 43, no. 2, pp. 233–240, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. Y. H. Li, Y. F. He, and Y. F. He, “Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma,” Cancer, vol. 106, no. 6, pp. 1320–1325, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  63. W. Yeo, W. M. Ho, P. Hui, P. K. S. Chan, K. C. Lam, J. J. Lee, and P. J. Johnson, “Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients,” Breast Cancer Research and Treatment, vol. 88, no. 3, pp. 209–215, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  64. K. Mimidis, C. Tsatalas, and C. Tsatalas, “Efficacy of lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B,” Acta Haematologica, vol. 107, no. 1, pp. 49–51, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Hamaki, M. Kami, E. Kusumi, J. I. Ueyama, S. Miyakoshi, S. I. Morinaga, and Y. Mutou, “Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab,” American Journal of Hematology, vol. 68, no. 4, pp. 292–294, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B: update of recommendations,” Hepatology, vol. 39, no. 3, pp. 857–861, 2004. View at Publisher · View at Google Scholar · View at PubMed
  67. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B,” Hepatology, vol. 34, no. 6, pp. 1225–1241, 2001. View at Publisher · View at Google Scholar · View at PubMed
  68. M. Picardi, F. Pane, and F. Pane, “Hepatitis B virus reactivation after fludarabine-based regimens for indolent non-Hodgkin's lymphomas: high prevalence of acquired viral genomic mutations,” Haematologica, vol. 88, no. 11, pp. 1296–1303, 2003. View at Google Scholar
  69. M. Miyagawa, M. Minami, and M. Minami , “Molecular characterization of a variant virus that caused de novo hepatitis B without elevation of hepatitis B surface antigen after chemotherapy with rituximab,” Journal of Medical Virology, vol. 80, no. 12, pp. 2069–2078, 2008. View at Publisher · View at Google Scholar · View at PubMed
  70. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B,” Hepatology, vol. 45, no. 2, pp. 507–539, 2007. View at Publisher · View at Google Scholar · View at PubMed
  71. A. S. F. Lok and B. J. McMahon, “Chronic hepatitis B: update 2009,” Hepatology, vol. 50, no. 3, pp. 661–662, 2009. View at Publisher · View at Google Scholar · View at PubMed
  72. Y. F. Liaw, N. Leung, and N. Leung, “Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update,” Liver International, vol. 25, no. 3, pp. 472–489, 2005. View at Publisher · View at Google Scholar · View at PubMed
  73. European Association for the Study of the Liver, “EASL clinical practice guidelines: management of chronic hepatitis B,” Journal of Hepatology, vol. 50, no. 2, pp. 227–242, 2009. View at Publisher · View at Google Scholar · View at PubMed
  74. K. Q. Hu, “Occult hepatitis B virus infection and its clinical implications,” Journal of Viral Hepatitis, vol. 9, no. 4, pp. 243–257, 2002. View at Publisher · View at Google Scholar
  75. W. Yeo, K. C. Lam, and K. C. Lam, “Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy,” Annals of Oncology, vol. 15, no. 11, pp. 1661–1666, 2004. View at Publisher · View at Google Scholar · View at PubMed
  76. N. Fukushima, T. Mizuta, and T. Mizuta, “Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier,” Annals of Oncology, vol. 20, no. 12, pp. 2013–2017, 2009. View at Publisher · View at Google Scholar · View at PubMed
  77. H. Tsubouchi, H. Kumada, and H. Kumada, “Prevention of immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection—joint report of the Intractable Liver Diseases Study Group of Japan and the Japanese Study Group of the Standard Antiviral Therapy for Viral Hepatitis,” Acta Hepatologica Japonica, vol. 50, no. 1, pp. 38–42, 2009. View at Publisher · View at Google Scholar
  78. S. Awerkiew, M. Däumer, and M. Däumer, “Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient,” Journal of Clinical Virology, vol. 38, no. 1, pp. 83–86, 2007. View at Publisher · View at Google Scholar · View at PubMed
  79. Y. Tsutsumi, Y. Yamamoto, J. Tanaka, M. Asaka, M. Imamura, and N. Masauzi, “Prevention of hepatitis B virus reactivation under rituximab therapy,” Immunotherapy, vol. 1, no. 6, pp. 1053–1061, 2009. View at Publisher · View at Google Scholar · View at PubMed
  80. M. Onozawa, S. Hashino, and S. Hashino, “Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection,” Transplantation, vol. 79, no. 5, pp. 616–619, 2005. View at Publisher · View at Google Scholar
  81. J. P. Allain, “Occult hepatitis B virus infection,” Transfusion Clinique et Biologique, vol. 11, no. 1, pp. 18–25, 2004. View at Publisher · View at Google Scholar · View at PubMed
  82. R. Liang, “How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation,” Blood, vol. 113, no. 14, pp. 3147–3153, 2009. View at Publisher · View at Google Scholar · View at PubMed
  83. S. Kusumoto, Y. Tanaka, M. Mizokami, and R. Ueda, “Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma,” International Journal of Hematology, vol. 90, no. 1, pp. 13–23, 2009. View at Publisher · View at Google Scholar · View at PubMed
  84. M. S. Dai, T. Y. Chao, W. Y. Kao, R. Y. Shyu, and T. M. Liu, “Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP,” Annals of Hematology, vol. 83, no. 12, pp. 769–774, 2004. View at Publisher · View at Google Scholar · View at PubMed
  85. M. J. Garcia-Rodriguez, M. A. Canales, D. Hernandez-Maraver, and F. Hernandez-Navarro, “Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?” American Journal of Hematology, vol. 83, no. 8, pp. 673–675, 2008. View at Publisher · View at Google Scholar · View at PubMed
  86. G. Perceau, N. Diris, O. Estines, C. Derancourt, S. Lévy, and P. Bernard, “Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma,” British Journal of Dermatology, vol. 155, no. 5, pp. 1053–1056, 2006. View at Publisher · View at Google Scholar · View at PubMed
  87. J. Gossmann, E.-H. Scheuermann, H.-G. Kachel, H. Geiger, and I. A. Hauser, “Reactivation of hepatitis B two years after rituximab therapy in a renal transplant patient with recurrent focal segmental glomerulosclerosis: a note of caution,” Clinical Transplantation, vol. 23, no. 3, pp. 431–434, 2009. View at Publisher · View at Google Scholar · View at PubMed
  88. W. Yeo and P. J. Johnson, “Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy,” Hepatology, vol. 43, no. 2, pp. 209–220, 2006. View at Publisher · View at Google Scholar · View at PubMed
  89. G. V. Papatheodoridis, S. Manolakopoulos, G. Dusheiko, and A. J. Archimandritis, “Therapeutic strategies in the management of patients with chronic hepatitis B virus infection,” Lancet Infectious Diseases, vol. 8, no. 3, pp. 167–178, 2008. View at Publisher · View at Google Scholar · View at PubMed
  90. S. K. Fung, P. Andreone, and P. Andreone, “Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation,” Journal of Hepatology, vol. 43, no. 6, pp. 937–943, 2005. View at Publisher · View at Google Scholar · View at PubMed
  91. M. E. Reff, K. Carner, and K. Carner, “Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20,” Blood, vol. 83, no. 2, pp. 435–445, 1994. View at Google Scholar
  92. M. Vigna-Perez, B. Hernández-Castro, O. Paredes-Saharopulos, D. Portales-Pérez, L. Baranda, C. Abud-Mendoza, and R. González-Amaro, “Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study,” Arthritis Research and Therapy, vol. 8, no. 3, article R83, 2006. View at Publisher · View at Google Scholar · View at PubMed